Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852845 | 0.95 | GRIN1 (0.32) | JAK3GRIN2BOPRM1OPRL1SLC6A9 | |
| SCHEMBL18121980 | 0.86 | JAK3 (0.34) | JAK3GRIN2BGRIN2COPRM1OPRL1 | |
| SCHEMBL24338565 | 0.85 | DPP4 (0.36) | JAK3GRIN2BGRIN2C | |
| SCHEMBL16751001 | 0.83 | GRIN1 (0.32) | JAK3GRIN2BGRIN1GRIN2A | |
| SCHEMBL24339026 | 0.81 | DPP4 (0.34) | GRIN2BGRIN2C | |
| SCHEMBL30310728 | 0.81 | GRIN1 (0.36) | GRIN2BOPRM1OPRL1SLC6A9HSD17B10 | |
| SCHEMBL8523550 | 0.81 | GRIN1 (0.36) | GRIN2BOPRM1OPRL1SLC6A9HSD17B10 | |
| SCHEMBL24620446 | 0.80 | GRIN2B (0.32) | GRIN2BGRIN2C | |
| SCHEMBL19852891 | 0.80 | — | — | |
| SCHEMBL24338556 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-18 | — | — | US | disclosed |
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-18 | — | — | US | disclosed |
| EP-3746442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152678-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152678-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2018026779-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | JAK3 4592/4885GRIN2B 5/4885GRIN2C 4/4885 |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | JAK3 4592/4885GRIN2B 5/4885GRIN2C 4/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | JAK3 4592/4885GRIN2B 5/4885GRIN2C 4/4885 |
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | JAK3 4525/4885GRIN2B 3/4885GRIN2C 5/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | JAK3 4592/4885GRIN2B 5/4885GRIN2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.